Georgia Atlas aspires to be the leading evidence-based and patient-focused cannabis brand in Georgia with a dedication to giving back.
About Us
Our
Mission.
We will integrate the latest in medical cannabis research, cultivation, and extraction technologies to produce pharmaceutical grade products.
Our operations will implement the Good Agricultural Collection Practices and Good Manufacturing Practices standards to ensure the highest levels of safety for all our patients.
Our corporate social and environmental responsibility plan highlights our commitment to giving back. Georgia Atlas is cannabis-based wellness done the way all companies should do it.
Our
Vision.
Georgia Atlas offers a total wellness solution designed by physicians, grounded in data, and tailored to the needs of Georgians. Our vision goes far beyond a portfolio of cannabis-based products.
Our Leadership.
Medical Board
In 2014, Dr. Smith founded and chaired the not-for-profit, Oil for Epilepsy, driven by his daughter’s development of a severe intractable seizure disorder, and her subsequent dramatic reduction in seizures by taking medical cannabis. His ceaseless efforts to establish a Medical Cannabis program in Georgia were instrumental in not only seeing the law passed, but also expanding the state’s list of qualified conditions to over 17.
He currently serves as the President-Elect of the Georgia College of Emergency Medicine (GCEP), the Vice President of the Medical Association of Georgia (MAG), Board of Directors for the Georgia Trauma Commission, Board of Directors for Gwinnett County Health Department, and is the Immediate Past-Chair of MAG’s Georgia Medical Political Action Committee. Dr. Smith is committed to using his role as a leader in the medical community to advocate for political change in the Medical Cannabis arena that directly benefits patients in Georgia.
Chief Research Officer
Dr. McNabb is the former CEO and Co-Founder of the Cannabis Community Care and Research Network (C3RN), a Massachusetts-based cannabis research company from 2018 – 2020 that aimed to improve the evidence-base related to medical cannabis therapies. C3RN, with UMass Dartmouth, led a two-year open cannabis consumer and patient research study to assess the impact on health, social, and economic outcomes. C3RN also led a Veterans Health and Medical Cannabis Research Study with UMass Dartmouth, and partners. C3RN was an approved qualified training vendor for the Massachusetts Cannabis Control Commission’s social equity training program. Dr. McNabb also holds over 15 years of global public health experience working in the areas of digital health, HIV/AIDS, maternal and child health, and family planning, working primarily in Africa and Haiti. She received her DrPH from Boston University School of Public Health and her MPH from the Johns Hopkins University School of Public Health.
Panel Members
Medical Advisory Panel
- Dr. James Smith
- Dr. Joshua W. Murfree Jr.
- Stanley Atkins II
- Dr. Roderick Stewart
- Dr. Steven Presciutti
- Dr. Michelle Lyon
- Dr. Derek Polly
- Dr. P. Tennent Slack
- Dr. Colin Lentz
- Dr. Deborah Miller
- Dr. Matt Lyon
- Dr. Nicole Cotton
- Dr. Carmen Sulton
- Dr. Margaret Wong
Scientific Advisory Panel
- Marion McNabb, DrPH, MPH
- Otha Smith III
- Chris McElvany
- Jermey Applen
- Jessica Baker
- Stanley Atkins II
- Janell Cleveland
Patient Advocacy Panel
- Bonnie Meshad
- Kathrine Lynch
- KJ Levenson
- Stanley Atkins II
- Yolanda Bennett
- Brian Pilling
- Luz Roman
- Stephen George
- Blue Quisquis